ArriVent BioPharma is a clinical-stage company developing oncology medicines, with an initial focus on solid tumors. Its lead candidate, firmonertinib (also known as furmonertinib), is an EGFR-targeted tyrosine kinase inhibitor advanced for non-small cell lung cancer, including underserved mutation subtypes. The pipeline also includes next-generation antibody-drug conjugates. The company has no commercial product revenue and serves the oncology development pathway rather than marketed drug sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -31.4 | — |
| Q3 2025 | 0 | — | -35 | — |
| Q4 2025 | 0 | — | -35.5 | — |
| Q1 2026 | 0 | — | -43.3 | — |
| Q2 2026 | 0 | — | -49.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: South Plains Financial, Inc. (SPFI), Orrstown Financial Services, Inc. (ORRF), AdaptHealth Corp. (AHCO), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY), Liberty Capital Corporation (GLIBA), InMode Ltd. (INMD)